This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Yun Yang
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Circular RNAs (circRNAs) that occupy gene expression at the transcriptional or post-transcriptional level have great potential to be biomarker for types of cancers. We have screened one altered circRNA named circ-ANAPC7 in acute myeloid leukemia (AML) before. In this study, we aimed to validate its expression by enlarging sample size and illuminating the diagnostic and monitoring value of circ-ANAPC7 in AML.
Methods
Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was supposed to confirm the expression of circ-ANAPC7 of AML patients. We assessed the correlation of circ-ANAPC7 and clinical variables using Spearman correlation test. Receiver operating characteristic (ROC) curve was carried out to evaluate the diagnostic value.
Results
Circ-ANAPC7 was first found to be upregulated in AML, and its expression was correlated to WBC counts and blast percentage in bone marrow. ROC curve analysis revealed that circ-ANAPC7 has significant value of AML diagnosis (AUC = 0.915, P < 0.001). Furthermore, the expression level of circ-ANAPC7 was changed accompanied with disease condition transformation.
Conclusions
Circ-ANAPC7 could be used as a biomarker to monitor disease condition of AML.
Keywords
Acute myeloid leukemia, circ-ANAPC7, biomarker
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 10 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Hematology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Yun Yang
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 10 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Hematology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Circular RNAs (circRNAs) that occupy gene expression at the transcriptional or post-transcriptional level have great potential to be biomarker for types of cancers. We have screened one altered circRNA named circ-ANAPC7 in acute myeloid leukemia (AML) before. In this study, we aimed to validate its expression by enlarging sample size and illuminating the diagnostic and monitoring value of circ-ANAPC7 in AML.
Methods
Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was supposed to confirm the expression of circ-ANAPC7 of AML patients. We assessed the correlation of circ-ANAPC7 and clinical variables using Spearman correlation test. Receiver operating characteristic (ROC) curve was carried out to evaluate the diagnostic value.
Results
Circ-ANAPC7 was first found to be upregulated in AML, and its expression was correlated to WBC counts and blast percentage in bone marrow. ROC curve analysis revealed that circ-ANAPC7 has significant value of AML diagnosis (AUC = 0.915, P < 0.001). Furthermore, the expression level of circ-ANAPC7 was changed accompanied with disease condition transformation.
Conclusions
Circ-ANAPC7 could be used as a biomarker to monitor disease condition of AML.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...